ArticleCureus2026
Growth Profile and Endocrine Dysfunction in Children Aged 2-10 Years With Transfusion-Dependent β-Thalassemia Major.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Advances in regular blood transfusion and iron chelation therapy have markedly improved survival in children with transfusion-dependent β-thalassemia major (TDT). As survival has increased, growth impairment and endocrine disorders related to chronic iron overload have become increasingly important causes of long-term morbidity. This study examined the prevalence of endocrine abnormalities and their relationship with growth parameters and iron overload in children with TDT. Methods A hospital-based cross-sectional study was conducted among 150 children aged 2-10 years with TDT attending a tertiary care center in northern India. Clinical details, anthropometric measurements, serum ferritin concentrations, and endocrine investigations, including thyroid function, glycemic profile, gonadal hormones, growth hormone, cortisol, calcium, parathyroid hormone, and vitamin D levels, were recorded. Correlation analyses and multivariable logistic regression were used to explore factors associated with endocrine dysfunction. Results Overall, 78.7% of children had at least one endocrine abnormality. Thyroid dysfunction (63.3%) and vitamin D deficiency (62.0%) were the most frequent disorders, followed by gonadal dysfunction (46.7%), serum cortisol abnormalities (41.3%), and low random growth hormone levels (38.7%). Older children had a greater burden of endocrine dysfunction than younger children (all p<0.001). Serum ferritin showed positive correlations with thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, and glycated hemoglobin, while negative correlations were observed with height-for-age Z-score, weight-for-age Z-score, free thyroxine, and serum cortisol (all p<0.001). Increasing age (adjusted OR: 1.32), higher serum ferritin levels (adjusted OR: 1.12 per 100 ng/mL increase), longer duration of transfusion therapy, and poor adherence to chelation therapy independently predicted endocrine dysfunction. Conclusions Endocrine abnormalities are common even in young children with TDT and are closely associated with increasing iron burden. Early endocrine evaluation, effective transfusion practices, good adherence to iron chelation therapy, and regular monitoring of iron overload may help reduce endocrine complications and support better growth outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.